Clinical Notes: Users Deem E-Cigs Safer MedPage Today In comments made to industry analysts at a meeting, the company's CEO Robert Bradway said Amgen would be launching biosimilar versions of bevacizumab (Avastin), adalimumab (Humira), infliximab (Remicade), trastuzumab (Herceptin), rituximab ... |
